Abbott files sNDA for stronger Simcor doses
This article was originally published in Scrip
Executive Summary
Abbott has filed an sNDA in the US requesting permission to market two new doses of Simcor (extended release niacin plus simvastatin), its fixed-dose dyslipidaemia combination product.